Ven4settembre
Programma
- 14:00Introduzione e saluti inizialiL. DEL MASTRO
- 14:10Saluti istituzionaliL. DEL MASTRO
- Moderatori: l. del mastro, s. de placido
- 14:20Lettura: 25 anni del gruppo GIMM. DE LAURENTIIS
- 14:40Il nuovo statuto del GIML. DEL MASTRO, S. DE PLACIDO
- Aggiornamento studi: Carcinoma mammario in fase precoce — Moderatori: a. fabi, a. gennari, d. generali
- 15:00GIM 10 CONSENT — A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatment of post-menopausal patients with endocrine-responsive early breast cancer.D. CAMPANELLA
- GIM 23 POSTER — Prospective observational study of adjuvant hormone treatment in estrogen-receptor positive premenopausal early breast cancer patientsL. ARECCO
- GIM 28 ELMER — EvoLution of Neoadjuvant TreatMent in 'triple-negative' or 'HER-2-positive' breast cancer diagnosed in the EaRly phase: retrospective multicentre study on the therapeutic approach most commonly adopted in the Italian oncology centresA. ROSSI
- GIM 26 TRASTHER — Observational study of effectiveness and safety of trastuzumab emtansine (T-DM1)F. POGGIO
- MATISSE — EvoLution of Neoadjuvant TreatMent in 'triple-negative' or 'HER-2-positive' breast cancerL. CARMISCIANO
- GIM 29 GIMOMIC — Observational, retrospective and prospective, non-interventional, multicentre national registry-based study to collect information on the use of genomic testing in the management of early stage HR+/HER2- breast cancer.C. BENVENUTI, P. DE PLACIDO
- GIM 31 NEO-AGILE — NEOadjuvant Abemaciclib and GIredestrant triaL in patients with ER-positive, HER2-negative Early breast cancerC. VON ARX
- GIM32 PERSEVEREX — Premenopausal Beast Cancer adjuvant therapy benefit according to OncotypE Dx testA. PALAZZO
- GIM 34 RARE — a phase III non inferiority trial evaluating safety of oMitting Adjuvant chemoTherapy in patients with Intermediate riSk early-stage hormone-receptor positive/HER2-negative breaSt cancer candidate to adjuvant abEmaciclibC. MOLINELLI
- Moderatori: f. puglisi, g. arpino, l. boni
- 16:30Presentazione nuove proposte
- 17:00Coffee Break
- Aggiornamento studi: Carcinoma mammario in stadio avanzato/metastatico — Moderatori: v. guarneri, s. cinieri, a. musolino
- 17:15GIM 12 TYPHER — A randomised, multicentre, open-label Phase II trial investigating activity of chemotherapy and lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) refractory to anti HER2 therapies.P. TRASACCO
- GIM 14 BIOMETA — Evaluation of medical treatments (chemotherapy, hormonal therapy and biological therapies) in metastatic breast cancer patients according to biologic subtype and line of treatment.F. POGGIO
- GIM 16 FEVEX — Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopausal women with hormone receptor positive (HR+) and human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC) previously treated with non steroidal aromatase inhibitors (NSAI): a multicentre, phase III trial.A. GRIECO
- GIM 21 LIQERBCEPT — Liquid Biopsy: intercepting mutational trajectories of HER2 breast cancer in patients under T-DM1 treatmentL. CARBOGNIN
- GIM 22 ERICA — Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study - ERICA trialM. TAFURO
- GIM 24 PALBO-BP — Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial - Palbo-BPA. CALTAVITURO
- GIM 27 THERAPY — Non-interventional, multicentric, prospective, observational study to describe the effectiveness of tucatinib in combination with capecitabine and trastuzumab in the treatment of metastatic HER-2 positive breast cancer patients in real world settingV. DI LAURO
- GIM 30 RAPID — An observational, multicenter study evaluating the safety of ReAl-life Pertuzumab and Trastuzumab Fixed Dose combination: the RAPID studyG. BUONO
- GIM 33 TRUTH — Trastuzumab-Deruxtecan (T-DXd) effectiveness in the treatment of early-lines HER2-positive metastatic breast cancer (MBC): a retrospective real-life analysis of patients treated in ItalyG. BUONO
- Moderatori: a. zambelli, e. blondeaux, m. lambertini
- 18:45Presentazione nuove proposte
- 19:15Chiusura lavori